Prof. Dr.Çağlayan Geredeli

  • İlgi Alanları
  • Kolon kanseri
  • Mide kanseri
  • Meme kanseri
  • Prostat kanseri
  • Akciğer kanseri
  • Jinekolojik kanserler
  • İmmünoterapi
  • Alternatif tıp

DÜNYA da  ve TÜRKİYE de uygulanmakta olan her türlü HEDEFE YÖNELİK İLAÇ TEDAVİSİ  (akıllı ilaç tedavisi), her türlü İMMÜNOTERAPİ ( Vucut direncini artırarak ve vücut savunma hücrelerini tümör hücresine hücum ettirerek tümörü öldürmektedir), her türlü KEMOTERAPİ ve Kanserli hastaların vücut direncini artıracak ALTERNATİF TIP ( ozon tedavisi , yüksek doz C vitamini ve curcumin gibi tedaviler) tedavileri ve FİTOTERAPİ uygulanmaktadır.

Eğitim ve Uzmanlık
1994 Selçuk Üniversitesi Tıp Fakültesi
2012 NEÜ Meram Tıp Fakültesi Tıbbi Onkoloji Uzmanı
2018 Tıbbi Onkoloji Doçenti

Deneyim
1994-1995 Kütahya Gediz Devlet Hastanesi
1995-1999 Dicle Üniversitesi Tıp Fakültesi Hastanesi İÇ hastalıkları
2000-2001 Şırnak Silopi Devlet hastanesi İç Hastalıkları Uzmanı ve Başhekimi
2002-2003 Ankara Polatlı SSK Hastanesi İç Hatalıkları Uzmanı
2004-2007 Ankara Polatlı Hayrettin Ekmen Devlet Hastanesi İç Hastalıkları uzmanı ve Başhekimi
2008-2009 Ankara Polatlı Duatepe Devlet Hastanesi İç Hastalıkları Uzmanı ve Başhekim Yard.
2010 -2012 Necemttin Erbakan Üniversitesi Meram Tıp Fakültesi Tıbbi Onkoloji Bölümü
2013-2014 Konya Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanı
2015-2017 İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Uzmanı
2018-2021 İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi Tıbbi Onkoloji Eğitim görevlisi
2022-2023 İstanbul Prof Dr. Cemil Taşcıoğlu Şehir Hastanesi Tıbbi Onkoloji Eğitim Sorumlusu

Kurs ve Sertifikalar
2010 Boğaziçi Üniversitesi İyi Klinik uygulamalar sertifikası 

Mesleki Üyelikler
Türk Tıbbi Onkoloji Derneği Üyesi
Onkolojik Klinik Araştırmalar Derneği Üyesi
Marmara Onkoloji Derneği Üyesi

Uluslararası hakemli dergilerde yayımlanan makaleler
1. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study Ayse Irem Yasin Sabin Göktas Aydin Bilge Sümbül, Lokman Koral, Melih Şimşek  Çağlayan Geredeli, Akın Öztürk, Perihan Perkin, Derya Demirtaş, Engin Erdemoglu
2. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.. Tumour biology : the journal of the International Society .
GEREDELİ ÇAĞLAYAN, ARTAÇ MEHMET,YILDIRIM MAHMUT SELMAN,İNAL ALİ,DEDE İSA,GÜLER TUNÇ,BÖRÜBAN MELİH CEM,KORAL LOKMAN,KARAAĞAÇ MUSTAFA,ZAMANİ AYŞEGÜL,ALTINOK TAMER,ARIBAŞ OLGUN KADİR,BOZCUK HAKAN,DEMİRKAZIK AHMET
3.FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.. World journal of surgical oncology, 16(1), 67
GEREDELİ ÇAĞLAYAN, YAŞAR Nurgül
4.The prognostic significance of the18F-fluorodeoxyglucose positron emissiontomography/computed tomography inearly?stage nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics

GEREDELİ ÇAĞLAYAN, ARTAÇ MEHMET,KOCAK İSMAİL,KORAL LOKMAN,SAKİN ABDULLAH,ALTINOK TAMER,KAYA BUĞRA,KARAAĞAÇ MUSTAFA

5. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).. Oncology, 83(3), 141-150

KAPLAN MUHAMMET ALİ,IŞIKDOĞAN ABDURRAHMAN,KOCA DOĞAN,KÜÇÜKÖNER MEHMET,GÜMÜŞAY ÖZGE,YILDIZ RAMAZAN,DAYAN A,DEMİR LÜTFİYE,GEREDELİ ÇAĞLAYAN,KOÇER MURAT,ARSLAN ÜLKÜ,İNAL ALİ,ÜNAL OLÇUN ÜMİT,MERT AG,BİLİCİ MEHMET,ÖZKAN METİN,ELKIRAN EMİN

6.Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2- positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.. Breast cancer

KAPLAN MUHAMMET ALİ,IŞIKDOĞAN ABDURRAHMAN,KOCA DOĞAN,KÜÇÜKÖNER MEHMET,GÜMÜŞAY ÖZGE,YILDIZ RAMAZAN,DAYAN A,DEMİR LÜTFİYE,GEREDELİ ÇAĞLAYAN,KOÇER MURAT,ARSLAN ÜLKÜ,İNAL ALİ,AKMAN TÜLAY,COŞKUN UĞUR,ŞENER N,İNANÇ MEVLÜDE,ELKIRAN EMİN TAMER,ÖZDEMİR NURİYE,DURNALI AG,SÜNER ALİ,ALICI S,TARHAN .

7. Efficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer. International Journal of Hematology and Oncology, 23(1), 1-6.

Karaca Halit,GEREDELİ ÇAĞLAYAN,KAPLAN MUHAMMET ALİ,DEMİRCİ UMUT,ALICI SÜLEYMEN,ARTAÇ MEHMET,IŞIKDOĞAN ABDURRAHMAN,BENEKLİ MUSTAFA,BALAKAN OZAN,Arpaci Erkan,Budakoğlu Burçin,UNCU DOĞAN,GÜLER TUNÇ,BERK VELİ,ÖZKAN METİN

8. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study..

İNAL ALİ,KOŞ FT,ALGIN EFGAN,YILDIZ RAMAZAN,DİKİLİTAŞ MUSTAFA,ÜNEK İLKAY TUĞBA,ÇOLAK D,ELKIRAN EMİN TAMER,HELVACI KAAN,GEREDELİ ÇAĞLAYAN,DANE FAYSAL,BALAKAN OZAN,KAPLAN MUHAMMET ALİ,DURNALI AG,HARPUTLUOĞLU HAKAN,GÖKSEL ÖZTÜRK GAMZE,ÖZDEMİR

9.Childhood, adolescents, and young adults (25 y) colorectal cancer: study of Anatolian Society of Medical Oncology.. Journal of pediatric hematology/oncology, 35(2), 83-89.

KAPLAN MUHAMMET ALİ,IŞIKDOĞAN ABDURRAHMAN,GÜMÜŞ MAHMUT,ARSLAN ÜLKÜ,GEREDELİ ÇAĞLAYAN,ÖZDEMİR NURİYE,KOCA DOĞAN,DANE FAYSAL,SÜNER ALİ,ELKIRAN EMİN TAMER,KÜÇÜKÖNER MEHMET,Şeker Metin,HELVACI KAAN,GÜLER TUNÇ,UNCU DOĞAN,İNAL ALİ,YILDIZ

10. Endocrine therapy alone vs. chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: a retrospective analysis of a multicenter study.. Journal of B.U.ON. : official journal of the

İNAL ALİ,AKMAN TÜLAY,YAMAN S,DEMİR ÖZTÜRK S,GEREDELİ ÇAĞLAYAN,BİLİCİ MEHMET,İNANÇ MEVLÜDE,HARPUTLUOĞLU HAKAN,DEMİRCİ UMUT,BALAKAN OZAN,HÜ YEŞİL ÇİNKİR,ALICI SÜLEYMEN,UYSAL SÖNMEZ ÖZLEM,GÖKSEL ÖZTÜRK GAMZE,GÖKÖZ DOĞU GAMZE,ÜNAL OLÇUN ÜMİT,TAMÖZLÜ TA,BÜYÜKBERBER SÜLEYMEN,BÖRÜBAN MELİH CEM,IŞIKDOĞAN AB.

11. Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study

İNAL ALİ,Kodaz Hilmi,Odabaşı Hatice,OCAK DURAN AYŞE,Şeker Metin,İNANÇ MEVLÜDE,ELKIRAN EMİN TAMER,GÜNAYDIN YUSUF,Menekşe Serkan,Öztürk Topçu Türkan,URAKÇI ZUHAT,Taştekin Didem,BİLİCİ MEHMET,Cihan Şener,GEREDELİ ÇAĞLAYAN,SEZER EMEL,UNCU DOĞAN,ARPACI ERKAN

12.Is lymph node ratio prognostic factor for survival in elderly patients with node positive breast cancer? The Anatolian Society of Medical Oncology.. Annali italiani di chirurgia, 84(2), 143-148.

İNAL ALİ,AKMAN TÜLAY,YAMAN S,Öztürk SC,GEREDELİ ÇAĞLAYAN,BİLİCİ MEHMET,İNANÇ MEVLÜDE,HARPUTLUOĞLU HAKAN,DEMİRCİ UMUT,SÜNER ALİ,Çınkır HY,ALICI SÜLEYMEN,ÇOLAK D,Sönmez OU,GÖKSEL ÖZTÜRK GAMZE,DOĞU GG,ENGİN HÜSEYİN,ÜNAL OLÇUN ÜMİT

13.Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study.. Contemporary Oncology

İnal Ali,Kos FT,Algın E,Unek İT,Çolak D,DANE FAYSAL,GEREDELİ ÇAĞLAYAN,IŞIKDOĞAN ABDURRAHMAN,Yıldız Ramazan,BERK VELİ

14.Pathologic and clinical characteristics of elderly patients with breast cancer: a retrospective analysis of a multicenter study . International surgery, 99(1), 2-7

İNAL ALİ,AKMAN TÜLAY,YAMAN S,ÖZTÜRK SC,GEREDELİ ÇAĞLAYAN,BİLİCİ MEHMET,İNANÇ MEVLÜDE,HARPUTLUOĞLU HAKAN,DEMİRCİ UMUT,BALAKAN OZAN,ÇANKIR HY,ALICI SÜLEYMEN,ÇOLAK D,SÖNMEZ OU,GÖKSEL ÖZTÜRK GAMZE,DOĞU GG,ENGİN HÜSEYİN,ÜNAL OLÇUN

15. Fulvestrant Efficacy in Artificial Menopausal Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Patients under 50 Years Old. International Journal

GEREDELİ ÇAĞLAYAN,

YAŞAR Nurgül

16. Rationale for Palliative Gastrectomy and Metastasectomy in Metastatic Gastric Cancer. International Journal of Current Research and Review, 10(7), 6-

Sakin Abdullah,Tambaş Makbule,YAŞAR Nurgül,GEREDELİ ÇAĞLAYAN,Seçmeler Şaban,Demir Cumhur,Alemdar Ali,GÜVEN HAKAN,Cihan Şener,

17. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study. Journal of BUON, 17, 102-105.

İNAL ALİ,KOŞ FT,ALGIN EFGAN,YILDIZ RAMAZAN,GEREDELİ ÇAĞLAYAN,ÜNEK İLKAY TUĞBA,ÇOLAK D,KÜÇÜKÖNER MEHMET,ELKIRAN EMİN TAMER,HELVACI KAAN,DANE FAYSAL,BALAKAN OZAN,KAPLAN MUHAMMET ALİ,AYŞE DURNALI,HARPUTLUOĞLU HAKAN,GÖKSEL ÖZTÜRK GAMZE,ÖZDEMİR

18. Efficacy of Pemetrexed or Pemetrexed Plus Cisplatin/Carboplatin in Pretreated Patients with Advanced Non–Small-Cell Lung Cancer. International Journal of Current Research and Review, 10(7), 22-27.

NAŞAR Nurgül,GEREDELİ ÇAĞLAYAN,

19. Predictive İmportance of Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio for Pathologic Complete Response in Locally Advanced Breast Cancer Patients ReceivingNeoadjuvant

GEREDELİ ÇAĞLAYAN, ARICI SERDAR

20. THE İMPACT OF RAMAZAN İ’TIKAF ON İMMUNE SYSTEM. Malaysian Journal of Public Health Medicine, 17(3), 104-108

EKER HASAN HÜSEYİN,ONUK MEHMET DERYA,GEREDELİ ÇAĞLAYAN,ABUDULİ MAİHEBURETİ

21. Comparison of Somatostatin and Famotidine for the Treatment of Nonvariceal Acute Upper Gastrointestinal Bleeding. International Journal of Current Research and Review, 10(8), 25-27.

GEREDELİ ÇAĞLAYAN,

22. Effectiveness and tolerability of FOLFIRINOX regime in metastatic pancreas cancer disease. The Medical Journal of Okmeydani Training and Research Hospital, 34(2)

GEREDELİ ÇAĞLAYAN, Cihan Şener,YAŞAR Nurgül,SAKİN ABDULLAH,CAN ORÇUN,ARTAÇ MEHMET,KARAAĞAÇ MUSTAFA,KORAL LOKMAN

23. Does tumor localization of operated NSCLC have an effect on relapse and survival?. The Medical Journal of Okmeydani Training and Research Hospital, 34(2)

GEREDELİ ÇAĞLAYAN,

24. Folfiri plus panitumumab as the first-line treatment in patients with KRAS wild-type metastatic colorectal cencer. A single center experience.. The Medical Journal of Okmeydani Training and Research

GEREDELİ ÇAĞLAYAN,

25. Comparison of in-Hospital Cardiopulmonary Resuscitation Results Before and After the Introduction Code Blue. Turkiye Klinikleri Journal of Anesthesiology Reanimation, 13(2), 78-85

ÇİÇEKÇİ Faruk,SİZER Çiğdem, GEREDELİ ÇAĞLAYAN,KARACA Halit,KARA FATİH,KARAİBRAHİMOĞLU ADNAN,

26. The prevalance of BRCA1/BRCA2 mutations among before age 60 women with triple negative breast cancer Single center experiance.. Erciyes Tıp Genetik Günleri

GEREDELİ ÇAĞLAYAN, Ertürk Biray

27. 40 Yaş Altı Meme Kanserli Türk Hastalarda BRCA1 ve BRCA2 Gen Mutasyon Oranları.Tek Merkez Deneyimi.. 2. Bursa Onkoloji Günleri

GEREDELİ ÇAĞLAYAN

28. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer

Dilek Çağlayan, Mehmet Zahid Koçak, Çağlayan Geredeli,  Ali Murat Tatlı, Sema Sezgin Göksu,  Melek Karakurt Eryılmaz,  Murat Araz & Mehmet Artaç

29. Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

Sabin Goktas Aydin,Burcin Cakan Demirel, Ahmet Bilici, Atakan Topcu, Musa Barış Aykan, Seda Kahraman,Ilgın Akbıyık, Muhammed Mustafa Atci, Omer Fatih Olmez, Arzu Yaren, Mehmet Ali Nahit Sendur, Caglayan Geredeli, Mesut Seker, Yuksel Urun, Nuri Karadurmus

30. Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Hanny Al-Samkari, Caglayan Geredeli, Cagatay Arslan, Ippokratis Korantzis, Gamze Gokoz Dogu, Marina Nechaeva

31. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

Ali Murat Tatli, Fatih Teker, Arif Hakan Onder, Fatih Kose, Caglayan Geredeli, Mustafa Karaagac, Muhammet Ali Kaplan, Mevlude Inanc, 

32. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wi̇ld-type patients treated with biologics second-line mCRC Mahmut Emre Yildirim, Mustafa Karaca, Mehmet Artac, Irfan Cicin, Caglayan Geredeli, Ahmet Alacacioglu,

33. The effect of BMI on the outcomes of CDK 4/6 inhibitor therapy in HR-positive metastatic breast cancer patients.

Dilek Çağlayan, Mehmet Zahid Kocak, Caglayan Geredeli, Ali Murat Tatli, Melek Karakurt Eryılmaz, Sema Sezgin Göksu

34. The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer

Sakin A.a · Sahin S.b · Yasar N.c · Demir C.c · Arici S.c · Geredeli C.c · Cihan S.

35. Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study

Muhammed Mustafa Atcı,1,* Çağlayan Geredeli,1 Seval Ay,2 Abdullah Sakin,3 Biray Ertürk,4 Şaban Seçmeler,

36.Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study

Kaplan M.A.a · Ozaydin S.b · Yerlikaya H.a · Karaagac M.c · Gumus M.d · Cil T.e · Yalcintas Arslan Ü.f · Ozdemir N.g · Sakin A.h · Bilici M.i · Koca D.j · Uysal M.k · Dane F.l · Sever Ö.N.m · Seker M.M.n · Oruc Seker Z.a · Can M.F.b · Geredeli C.c · Aksoy A.o · Pilanci K.N.p · Ozturk Topcu T.q · Isikdogan A.

37. Mean platelet volume and platelet distribution width correlates with prognosis of early colon cancer

Aysegul Sakin1 , Suleyman Sahin2 , Abdullah Sakin3 , Fatih Karatas4 , Nilay Sengul Samanci5 , Nurgul Yasar6 , Serdar Arici6 , Cumhur Demir6 , Caglayan Geredeli6 , Okan Dikker7 , Sener Cihan6

38. Can 68Ga-PSMA PET/CT-derived prostate-specific membrane antigen expression parameters predict prostate-specific antigen response to enzalutamide treatment?

Karyağar, Savaşa; Güven, Osmana; Karyağar, Sevda Sağlampinara; Arici, Serdarb; Selvi, Oğuzhanb; Geredeli, Çağlayanb; Özülker, Filiza

39…Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors

AbdullahSakin,aOrcunCan,bSerdarAriciMD,b,NurgulYasar,bCaglayanGeredeli,bCumhurDemir,bSenerCihan.

40…Effect of Pretreatment Platelet Parameters on Survival in Limited Disease Small Cell Lung Cancer

Abdullah Sakin,1,* Nurgul Yasar,2 Serdar Arici,2 Cumhur Demir,2 Caglayan Geredeli,2 Ferdi Aksaray,3 Selver Isik,4 and Sener Cihan2

41. Factors affecting survival in patients with isolated livermetastatic colorectal cancer treated with local ablative or surgical treatments for liver metastasis

Abdullah Sakin1 , Suleyman Sahin2 , Muhammed Mustafa Atci3 , Nurgul Yasar3 , Caglayan Geredeli3 , Serkan Aribal4 , Ali Alemdar5 , Fatih Karatas6 , Sener Cihan3

42. The Effect of Body Mass Index on Treatment Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Platinum-Based Therapy
Aysegul Sakin, Suleyman Sahin, Muhammed Mustafa atci, Nurgul Yasar, Cumhur Demir, Caglayan Geredeli

43. The effects of diabetes and fasting plasma glucose on treatment of breast cancer with neoadjuvant chemotherapy

SerdarAricia,CaglayanGeredeliaSabanSecmeleraRuhperCekinaAbdullahSakinbSenerCihana

44. The Clinical Importance of Androgen Receptor Status in Response to Neoadjuvant Chemotherapy in Turkish Patients with Local and Locally Advanced Breast Cancer

Arici S.a · Sengiz Erhan S.b · Geredeli C.a · Cekin R.a · Sakin A.c · Cihan S.a

45. Effect of type 2 diabetes mellitus on survival in metastatic pancreatic cancer

Ayşegül Sakin 1 , Süleyman Şahin 2 , Abdullah Sakin 3 , Muhammed Mustafa Atci 4 , Çağlayan Geredeli 4 , Şener Cihan 4

46. Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy

AbdullahSakinaSuleymanSahinbNurgulYasarcCumhurDemircSerdarAricicCaglayanGeredelicSenerCihanc

47. Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population

Caglayan Geredeli,1Nurgul Yasar,1and Abdullah Sakin